Active Ingredient(s): Erenumab-aooe
FDA Approved: * May 17, 2018
Pharm Company: * AMGEN INC
Category: Migraine / Tension Headache

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Aimovig Overview

Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.[2][3][4] It was the first of the group of CGRPR antagonists to be FDA approved in 2018.[5] It is a form of monoclonal antibody therapy in which antibodies are used to block the receptors for the protein CGRP, thought to play a major role in starting migraines.[6&am...

Read more Aimovig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Aimovig Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 70mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Aimovig: (4 results)

Sorted by National Drug Code
  • 55513-840 Aimovig 70 mg/ml Subcutaneous Injection by Amgen Inc
  • 55513-841 Aimovig 70 mg/ml Subcutaneous Injection by Amgen Inc
  • 55513-842 Aimovig 140 mg/ml Subcutaneous Injection, Solution by Amgen Inc
  • 55513-843 Aimovig 140 mg/ml Subcutaneous Injection, Solution by Amgen Inc

Other drugs which contain Erenumab-aooe or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 17 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA